Compare SLN & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLN | PAYS |
|---|---|---|
| Founded | 1994 | 2001 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.4M | 293.4M |
| IPO Year | N/A | 1998 |
| Metric | SLN | PAYS |
|---|---|---|
| Price | $6.57 | $5.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $39.67 | $8.06 |
| AVG Volume (30 Days) | 314.1K | ★ 372.6K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | $25,830,000.00 | ★ $74,879,428.00 |
| Revenue This Year | N/A | $41.20 |
| Revenue Next Year | N/A | $20.62 |
| P/E Ratio | ★ N/A | $42.18 |
| Revenue Growth | ★ 40.39 | 32.61 |
| 52 Week Low | $1.97 | $1.80 |
| 52 Week High | $8.08 | $8.88 |
| Indicator | SLN | PAYS |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 52.34 |
| Support Level | $5.95 | $5.11 |
| Resistance Level | $6.60 | $5.60 |
| Average True Range (ATR) | 0.53 | 0.19 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 41.33 | 60.00 |
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.